利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.018 秒)

    Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
    3.
    发明授权
    Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders 有权

    公开(公告)号：US11207337B2

    公开(公告)日：2021-12-28

    申请号：US16820767

    申请日：2020-03-17

    申请人： Janssen Pharmaceutica NV

    发明人： Norman R. Rosenthal ,  Paul Rothenberg ,  David C. Polidori ,  Douglas K. Ways ,  Peter P. Stein

    IPC分类号： A61K31/7042 ,  A61K31/135 ,  A61K31/137

    摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS
    4.
    发明申请
    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS 审中-公开

    公开(公告)号：US20200215090A1

    公开(公告)日：2020-07-09

    申请号：US16820767

    申请日：2020-03-17

    申请人： Janssen Pharmaceutica NV

    发明人： Norman R. Rosenthal ,  Paul Rothenberg ,  David C. Polidori ,  Douglas K. Ways ,  Peter P. Stein

    IPC分类号： A61K31/7042 ,  A61K31/137 ,  A61K31/135

    摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS
    7.
    发明申请
    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS 审中-公开

    公开(公告)号：US20190142855A1

    公开(公告)日：2019-05-16

    申请号：US16245682

    申请日：2019-01-11

    申请人： Janssen Pharmaceutica NV

    发明人： Norman R. Rosenthal ,  Paul Rothenberg ,  David C. Polidori ,  Douglas K. Ways ,  Peter P. Stein

    IPC分类号： A61K31/7042 ,  A61K31/135 ,  A61K31/137

    摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS
    8.
    发明申请
    CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS 审中-公开
    用于治疗肥胖和肥胖相关疾病的卡尼普利嗪和苯那司敏联合治疗

    公开(公告)号：US20170071970A1

    公开(公告)日：2017-03-16

    申请号：US15262038

    申请日：2016-09-12

    申请人： Janssen Pharmaceutica NV

    发明人： Norman R. Rosenthal ,  Paul Rothenberg ,  David C. Polidori ,  Douglas K. Ways ,  Peter P. Stein

    IPC分类号： A61K31/7042 ,  A61K31/135

    CPC分类号： A61K31/7042 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

    摘要翻译： 本发明涉及包括给予canagliflozin和phentermine治疗肥胖症和肥胖相关疾病的协同治疗的用途。 更具体地，本发明涉及用于治疗肥胖症，促进体重减轻和/或抑制食欲的共同治疗; 用于治疗，延缓，减缓代谢紊乱（包括例如2型糖尿病）的进展和/或预防; 用于治疗，延缓，减缓肾或脂肪性肝病的进展和/或预防（或包括例如NASH，NAFLD等）; 用于治疗，延迟，减缓睡眠障碍（包括例如睡眠呼吸暂停）的进展和/或预防和/或预防睡眠障碍。 用于提供心血管保护; 用于治疗，延迟，减缓心血管事件进展和/或预防心血管事件（包括主要不良心脏事件（MACE）），如心肌梗塞，不稳定型心绞痛，心血管死亡，血运重建，致命或非致命性脑血管意外，外周动脉病变，主动脉事件 ，由于充血性心力衰竭住院治疗等）; 和/或用于延长或延长使用寿命。